IBA, a prominent player in particle accelerator technology, recently unveiled a groundbreaking solution, myQA Blue Phantom³, at the ESTRO 2025 annual congress in Vienna, Austria. This innovative system is poised to revolutionize radiotherapy by enhancing precision and efficiency in treatment delivery and quality assurance.
myQA Blue Phantom³ is specifically designed for rapid and high-precision quality assurance and commissioning processes. It boasts the fastest automatic leveling capability in the market, completing the task in under 30 seconds. This feature significantly streamlines the commissioning process, saving crucial time. Medical physicists can leverage real-time, contactless positioning control with certified measurement precision, ensuring consistent and reproducible results.
IBA’s commitment to advancing the quality and precision of radiation therapy is evident through this launch. With over five decades of experience in the dosimetry market, IBA has established itself as a trusted partner for leading linac manufacturers. By providing clinicians with cutting-edge tools, IBA aims to enhance patient safety and treatment effectiveness, pushing the boundaries of quality assurance innovation.
Jean-Marc Bothy, President of IBA Dosimetry, emphasized the company’s dedication to innovation, integrating the latest advancements in radiation therapy and imaging into their products. The myQA Blue Phantom³ offering includes features like the fastest auto-leveling in the market, an embedded reference-class electrometer, and enhanced connectivity with major treatment devices available today.
IBA, headquartered in Louvain-la-Neuve, Belgium, is a global leader in particle accelerator technology. The company’s expertise extends to various fields, including proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry. Employing approximately 2,100 individuals worldwide, IBA is committed to upholding the highest standards of social and environmental performance as a certified B Corporation.
Listed on the EURONEXT stock exchange, IBA continues to drive innovation in the realm of radiation therapy. The launch of myQA Blue Phantom³ signifies a significant milestone in the company’s journey, marking 50 years since introducing the market’s first digital water phantom. This latest offering underscores IBA’s commitment to enabling healthcare professionals to deliver safe and effective treatments, ultimately benefiting patients worldwide.
For more information about IBA and its range of products and services, visit www.iba-worldwide.com. For media inquiries, contact Olivier Lechien, Corporate Communication Director, at communication@iba-group.com or ICR Healthcare at IBA@icrhealthcare.com.